IRB Study Number 25-020
Status Recruiting
Phase Phase 4
Location U Building - Mellen Center
Institute Neurological Institute
Description
The purpose of this study is to evaluate safety and effectiveness of BRIUMVI® (ublituximab-xiiy), as well as gain insight into the treatment experience in a real-world setting. BRIUMVI® was approved by the FDA in December 2022.
Participation involves evaluation of 10 infusions over 192 weeks of therapy, with study visits being same day as clinical appointments. Activities include screening assessment, data collection, and questionnaires.
Inclusion Criteria
- Age 18+
- Diagnosed with relapsing forms of MS
- No prior BRIUMVI® infusion before study start
Exclusion Criteria
- Recent live or live-attenuated vaccination
- Active infection such as Hepatitis B
- Concurrent participation in other MS trials or treatments
